Welcome to our dedicated page for Psyence Biomedical Ltd. news (Ticker: PBM), a resource for investors and traders seeking the latest updates and insights on Psyence Biomedical Ltd. stock.
Psyence Biomedical Ltd. (Nasdaq: PBM), also known as Psyence BioMed, is a biopharmaceutical and life sciences biotechnology company focused on nature-derived psilocybin and ibogaine-based psychedelic medicine. Its news flow reflects activity across clinical development, manufacturing, capital markets, and strategic partnerships.
Readers of the PBM news page can expect updates on the company’s Phase IIb clinical trial evaluating psilocybin-assisted psychotherapy for Adjustment Disorder in palliative care or in patients with cancer. News releases describe milestones such as patient dosing, expansion of clinical sites in Australia, and ethics approvals for the use of PsyLabs’ psilocybin product in the trial.
The company also issues announcements on its ibogaine operations and supply chain, including the establishment of sustainable iboga bark sourcing in Africa and the production of GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) and Total Alkaloid Extracts through its partner PsyLabs. These updates highlight progress in securing psychedelic active pharmaceutical ingredients for clinical and therapeutic markets.
Other PBM news items cover strategic investments and financial decisions, such as follow-on investments in PsyLabs, share consolidation (reverse stock split) actions, and capital management frameworks that include potential share repurchase programs, as described by the company. Communications may also address leadership changes, board appointments, and corporate governance developments disclosed in conjunction with SEC filings.
In addition, Psyence BioMed publishes news on its psilocybin longevity research initiative, which examines biological markers associated with aging, and on its broader positioning in the emerging psychedelics and longevity sectors. Investors and observers who follow PBM news can use this page to track the company’s clinical progress, manufacturing capabilities, and regulatory and capital markets updates over time.
Psyence BioMed (Nasdaq: PBM) adjourned its annual and special shareholder meeting scheduled for January 22, 2026 to February 12, 2026 at 9:00 a.m. New York Time / 4:00 p.m. Cape Town Time. The reconvened Meeting will be held at Venture Workspace Riverlands, Office Building 4, Riverlands, 51 Gogosoa Street, Observatory, Cape Town, 7935, South Africa.
The adjournment occurred because the requisite shareholder quorum was not achieved. The company is working with its proxy agents to help obtain quorum for the February 12, 2026 meeting. The record date remains close of business on December 23, 2025. For details of the Meeting business, see the company notice of meeting and management information circular dated January 2, 2026, filed on EDGAR.
Psyence BioMed (Nasdaq: PBM) announced on January 20, 2026 that it has postponed the previously announced 1-for-6.25 reverse stock split, which had been intended to become effective at market open on January 20, 2026. The Board retains discretion to determine if and when the reverse split will be effected.
The company said it will issue a subsequent press release and file any required Nasdaq notifications before setting a new effective date. Until a new date is set, PBM will continue to trade unadjusted on the Nasdaq Capital Market under ticker PBM and CUSIP 74449F308.
Psyence BioMed (Nasdaq: PBM) announced the effective date for a 1-for-6.25 reverse stock split. The consolidation was approved by the board on December 4, 2025, and common shares are expected to trade on a post-consolidated basis starting at market open on January 20, 2026. At the effective time every 6.25 issued shares will be combined into one share; warrants and other equity instruments will be adjusted proportionately. The company had 6,388,604 shares outstanding as of January 14, 2026, which will become 1,022,177 post-consolidation. Trading will remain under the symbol PBM with new CUSIP 74449F407. Fractional shares will be rounded per the announced rules and brokerage-held shares may reflect the change with delay.
Psyence BioMed (Nasdaq: PBM) announced that its Board approved a 2026 Financial Strategy and Capital Management Framework that authorizes a potential share repurchase program. The program allows the company to repurchase common shares from time to time, subject to liquidity, valuation, regulatory, Nasdaq, and corporate law conditions, and would be executed through an independent third-party broker. Repurchases may occur over the next six to twelve months if prices reflect a significant discount to the Board's assessment of underlying value, provided operational liquidity and planned clinical and regulatory milestones remain funded. The company is not obligated to repurchase shares and may modify or terminate the program.
Psyence BioMed (Nasdaq: PBM) announced a manufacturing and corporate milestone on January 5, 2026. The company, via PsyLabs, produced GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) derived from a naturally extracted, ethically sourced African supply, framed as the first Nasdaq-listed company to achieve this.
Conversion to the hydrochloride salt improves stability, solubility, purity, and dosing precision for clinical use. Psyence reported a $12 million cash balance, no debt, an active Phase 2b psilocybin clinical trial, and a Board change: Christopher Bull resigned (effective Dec 1, 2025) and Graham Patrick was appointed.
Psyence BioMed (Nasdaq: PBM) announced Bellberry Human Research Ethics Committee approval to use PsyLabs’ psilocybin product (NPX5) in its ongoing Phase IIb trial for adjustment disorder in cancer patients. The amendment covers all participating sites including Empax Centre, Mind Medicine Australia Clinic, and Paratus Clinical Research in Melbourne, and reflects updated protocol, investigator brochure, and participant materials.
The Phase IIb trial will enroll approximately 87 participants, test two therapeutic doses versus a low-dose comparator with structured psychotherapy, and is tracking to deliver top-line results in 2026. The company reports approximately USD $9.5 million in cash and no debt and emphasizes strengthened vertical integration, GMP manufacturing, and supply-chain control via its investment in PsyLabs.
Psyence BioMed (Nasdaq: PBM) CEO Jody Aufrichtig summarized 2025 clinical and corporate milestones and outlined 2026 priorities. Key points include:
- Initiation and dosing of first patients in a Phase IIb psilocybin-assisted psychotherapy trial for Adjustment Disorder in palliative care.
- Multi-million-dollar follow-on investment in PsyLabs to secure GMP nature-derived psilocybin and ibogaine supply and a reported breakthrough in high-purity ibogaine production.
- Regulatory momentum in Australia with a TGA public consultation that could enable supervised access via the Authorised Prescriber framework.
- Company finished the year debt free with over USD $9 million cash and plans to accelerate enrollment, expand manufacturing, and pursue longevity-focused indications in 2026.
Psyence BioMed (Nasdaq: PBM) launched a psilocybin longevity research program in collaboration with South African academic researchers, positioning the company as the first publicly listed firm to investigate psilocybin’s effects on biological aging markers. The initiative will test biomarkers for cellular stress, inflammation, mitochondrial function, telomere length and behavioural healthspan indicators under the leadership of Dr. Tanya Calvey, PhD. The company has commenced work and expects full acceleration early in the new year following ethics approval. The release cites preclinical findings including a >50% lifespan increase in human skin and lung cells with psilocin.
Psyence BioMed (Nasdaq: PBM) announced it secured a sustainable, high‑potency supply of iboga bark via partner PsyLabs to support clinical development of pharmaceutical‑grade ibogaine for substance use disorders and research markets.
The company received an initial 50 kg shipment being processed into ibogaine HCl and Total Alkaloid Extracts, with PsyLabs’ material described as GMP‑compliant. The collaboration emphasizes ethical sourcing, sustainability, and benefit‑sharing with source communities to build a vertically integrated supply chain for clinical research.
Psyence BioMed (Nasdaq: PBM) announced a strategic investment in PsyLabs to establish ibogaine operations and manufacturing in Africa, with PsyLabs operating an EU GMP-grade facility in Southern Africa.
The move gives PBM vertical integration across cultivation, extraction, and purification, positioning the company with traceable supply from the ibogaine source and control of quality for research and commercial development.
The release cites rising global momentum for ibogaine research, including a $50 million Texas research allocation in 2025 and recent pharmaceutical M&A activity around ibogaine analogs.